CL2021002918A1 - Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares - Google Patents
Composiciones y métodos de oximetazolina para el tratamiento de trastornos ocularesInfo
- Publication number
- CL2021002918A1 CL2021002918A1 CL2021002918A CL2021002918A CL2021002918A1 CL 2021002918 A1 CL2021002918 A1 CL 2021002918A1 CL 2021002918 A CL2021002918 A CL 2021002918A CL 2021002918 A CL2021002918 A CL 2021002918A CL 2021002918 A1 CL2021002918 A1 CL 2021002918A1
- Authority
- CL
- Chile
- Prior art keywords
- oxymetazoline
- compositions
- methods
- treatment
- ocular disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente divulgación está dirigida a composiciones que comprenden oximetazolina y métodos para estabilizar composiciones de oximetazolina para almacenamiento a largo plazo. La presente divulgación también está dirigida a composiciones que comprenden oximetazolina y métodos para tratar diversos trastornos oculares relacionados con párpados caídos, tales como ptosis, en un sujeto que comprende administrar al sujeto composiciones que comprenden oximetazolina.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962844069P | 2019-05-06 | 2019-05-06 | |
US201962843819P | 2019-05-06 | 2019-05-06 | |
US16/716,014 US10799481B1 (en) | 2019-05-06 | 2019-12-16 | Compositions and methods for treating ocular disorders |
US16/715,998 US10814001B1 (en) | 2019-05-06 | 2019-12-16 | Oxymetazoline compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021002918A1 true CL2021002918A1 (es) | 2022-08-19 |
Family
ID=72750169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021002918A CL2021002918A1 (es) | 2019-05-06 | 2021-11-05 | Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares |
Country Status (17)
Country | Link |
---|---|
US (11) | US10799481B1 (es) |
EP (1) | EP3965737A1 (es) |
JP (2) | JP7141420B2 (es) |
KR (3) | KR102410503B1 (es) |
CN (2) | CN117045596A (es) |
AU (1) | AU2020268329A1 (es) |
BR (1) | BR112021022404A2 (es) |
CA (1) | CA3139443A1 (es) |
CL (1) | CL2021002918A1 (es) |
CO (1) | CO2021015265A2 (es) |
IL (1) | IL287831A (es) |
MA (1) | MA55895A (es) |
MX (1) | MX2021013516A (es) |
PE (1) | PE20220384A1 (es) |
SG (1) | SG11202112272TA (es) |
WO (1) | WO2020227260A1 (es) |
ZA (1) | ZA202108950B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120225918A1 (en) * | 2011-03-03 | 2012-09-06 | Voom, Llc | Compositions and Methods for Non-Surgical Treatment of Ptosis |
US20240156786A1 (en) | 2021-03-03 | 2024-05-16 | Voom, Llc | Compositions and methods for treatment of blepharitis |
WO2023079427A1 (en) * | 2021-11-03 | 2023-05-11 | Avaca Pharma Private Limited | Ophthalmic compositions and methods thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE51421B1 (en) | 1980-08-01 | 1986-12-24 | Smith & Nephew Ass | Ophthalmic compositions containing triamterene |
US5459133A (en) | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
US5888493A (en) | 1996-12-05 | 1999-03-30 | Sawaya; Assad S. | Ophthalmic aqueous gel formulation and related methods |
DE10337186A1 (de) * | 2003-08-13 | 2005-03-17 | Merck Patent Gmbh | Wässrige Wirkstoff-Lösung |
US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
JP2006131628A (ja) * | 2004-10-08 | 2006-05-25 | Rohto Pharmaceut Co Ltd | オキシメタゾリン含有水性組成物 |
US8758816B2 (en) | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
AU2007227091B2 (en) | 2006-03-17 | 2013-02-07 | Johnson & Johnson Vision Care, Inc. | Stabilized ophthalmic compositions comprising oxidatively unstable components |
AU2007243334A1 (en) | 2006-04-26 | 2007-11-08 | Aciex Therapeutics, Inc. | Compositions for the treatment and prevention of eyelid swelling |
US8466203B2 (en) * | 2006-12-06 | 2013-06-18 | David Choohyun Paik | Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds |
US20090281156A1 (en) * | 2007-12-21 | 2009-11-12 | Schering-Plough Healthcare Products, Inc, | Enhancing photostabilization of oxymetazoline |
SI2262506T1 (sl) * | 2008-03-11 | 2014-07-31 | Alcon Research, Ltd. | Močno flokulirane suspenzije triamcinolon acetonida z nizko viskoznostjo za intravitrealno injekcijo |
EP2437602A4 (en) * | 2009-06-05 | 2014-02-19 | Aciex Therapeutics Inc | OPHTHALMIC FORMULATIONS, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THEIR USE |
US20120082625A1 (en) | 2010-09-28 | 2012-04-05 | Michael Graeber | Combination treatment for rosacea |
AU2011327785A1 (en) * | 2010-11-08 | 2013-03-07 | Healor Ltd. | Buffered ophthalmic compositions and methods of use thereof |
AU2011336449B2 (en) | 2010-12-03 | 2016-07-07 | Epi Health, Llc | Pharmaceutical cream compositions comprising oxymetazoline |
US20120225918A1 (en) | 2011-03-03 | 2012-09-06 | Voom, Llc | Compositions and Methods for Non-Surgical Treatment of Ptosis |
WO2013177594A2 (en) | 2012-05-25 | 2013-11-28 | Xlear, Inc. | Xylitol-based anti-mucosal compositions and related methods and compositions |
UA119324C2 (uk) | 2013-04-02 | 2019-06-10 | Теміс Медікер Лімітед | Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні |
EP3047712B1 (en) | 2013-09-18 | 2021-04-21 | Mycronic AB | Method, system and device for handling pallets in a smt system |
ES2796871T3 (es) | 2014-06-11 | 2020-11-30 | Epi Health Llc | Formulaciones de oximetazolina estabilizadas y sus usos |
US11052094B2 (en) | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
US20170312335A1 (en) * | 2015-12-30 | 2017-11-02 | Lubris Llc | Topical use of prg4 for treatment of allergy and symptoms of inflammation |
WO2017132410A1 (en) | 2016-01-26 | 2017-08-03 | Frank Litvack | Compositions and uses of alpha-adrenergic agents |
CN105997856A (zh) * | 2016-06-24 | 2016-10-12 | 魏威 | 盐酸羟甲唑啉滴眼液及其制备方法 |
US11246816B2 (en) | 2016-06-30 | 2022-02-15 | The Procter And Gamble Company | Shampoo compositions comprising a chelant |
-
2019
- 2019-12-16 US US16/716,014 patent/US10799481B1/en active Active
- 2019-12-16 US US16/715,998 patent/US10814001B1/en active Active
-
2020
- 2020-03-16 JP JP2020045468A patent/JP7141420B2/ja active Active
- 2020-04-01 CN CN202310901249.9A patent/CN117045596A/zh active Pending
- 2020-04-01 CN CN202010249167.7A patent/CN111888326B/zh active Active
- 2020-04-27 KR KR1020200050837A patent/KR102410503B1/ko active IP Right Grant
- 2020-05-05 PE PE2021001852A patent/PE20220384A1/es unknown
- 2020-05-05 MX MX2021013516A patent/MX2021013516A/es unknown
- 2020-05-05 SG SG11202112272TA patent/SG11202112272TA/en unknown
- 2020-05-05 BR BR112021022404A patent/BR112021022404A2/pt unknown
- 2020-05-05 AU AU2020268329A patent/AU2020268329A1/en active Pending
- 2020-05-05 EP EP20729894.4A patent/EP3965737A1/en active Pending
- 2020-05-05 WO PCT/US2020/031425 patent/WO2020227260A1/en unknown
- 2020-05-05 CA CA3139443A patent/CA3139443A1/en active Pending
- 2020-05-05 MA MA055895A patent/MA55895A/fr unknown
- 2020-10-05 US US17/063,416 patent/US10940138B2/en active Active
- 2020-10-07 US US17/064,915 patent/US10898573B1/en active Active
-
2021
- 2021-01-21 US US17/154,676 patent/US11103482B2/en active Active
- 2021-03-08 US US17/194,559 patent/US11324722B2/en active Active
- 2021-08-30 US US17/461,052 patent/US11311515B2/en active Active
- 2021-09-24 JP JP2021155526A patent/JP2021191802A/ja active Pending
- 2021-11-04 IL IL287831A patent/IL287831A/en unknown
- 2021-11-05 CL CL2021002918A patent/CL2021002918A1/es unknown
- 2021-11-11 ZA ZA2021/08950A patent/ZA202108950B/en unknown
- 2021-11-11 CO CONC2021/0015265A patent/CO2021015265A2/es unknown
-
2022
- 2022-04-25 US US17/728,860 patent/US11541036B2/en active Active
- 2022-05-09 US US17/662,494 patent/US11701343B2/en active Active
- 2022-06-14 KR KR1020220072209A patent/KR102663319B1/ko active IP Right Grant
- 2022-12-23 US US18/146,127 patent/US20230355587A1/en active Pending
-
2023
- 2023-06-08 US US18/331,688 patent/US20240033250A1/en active Pending
-
2024
- 2024-04-29 KR KR1020240057166A patent/KR20240060580A/ko active Application Filing
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021015265A2 (es) | Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares | |
CL2016002812A1 (es) | Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación. | |
AR120961A2 (es) | Método y composición para tratar hipertensión ocular y glaucoma | |
TW201613588A (en) | Ophthalmic composition | |
BR112013019257A2 (pt) | composição de androgênio para tratar uma condição oftálmica | |
CY1122565T1 (el) | Συνθεσεις και μεθοδοι μη χειρουργικης θεραπειας βλεφαροπτωσης | |
BR112017024531A2 (pt) | lentes intraoculares ajustáveis por luz usando nanopartículas de conversão ascendente e luz do infravermelho próximo (nir) | |
WO2016172712A3 (en) | Ophthalmic composition | |
EA201591743A8 (ru) | СТИМУЛЯТОРЫ sGC | |
CO2021006075A2 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
ECSP16072941A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
CL2020002734A1 (es) | Tratamientos para la presbicia | |
AR097209A1 (es) | Guía quirúrgica y software de planificación para el tratamiento del astigmatismo | |
MX2020005217A (es) | Composicion oftalmica y dispositivo de administracion de la misma. | |
CO2017001454A2 (es) | Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares | |
IN2014CN02153A (es) | ||
BR112014010376A2 (pt) | medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima | |
AU2018341331A1 (en) | Improvement in cognitive function with fenfluramine | |
BR112015022577A2 (pt) | moduladores ship1 e métodos relacionados a esse | |
BR112017020132A2 (pt) | métodos para promover o crescimento capilar ou prevenir a perda de cabelo em um indivíduo e para preparar uma composição, e, composição | |
MX2016012933A (es) | Composiciones de relleno de tejidos y metodos de uso. | |
BR112019000504A2 (pt) | métodos e composições poliméricas para o tratamento de descolamento de retina e outros distúrbios oculares | |
MX2020006309A (es) | Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis. | |
EA201990752A1 (ru) | Офтальмологический состав, содержащий цитиколин, переносимый липосомой, для лечения глаукомы | |
EA201591626A1 (ru) | Искусственные факторы транскрипции для лечения заболеваний, вызываемых гаплонедостаточностью opa1 |